Based in Israel, Aviceda is a startup. Brouky records 1 investor associated with the company.
Aviceda develops novel glyco-immune checkpoint therapeutics focusing on treatments for immune-mediated diseases, with a lead program targeting macular degeneration.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.